An invention patent based on the use of CXCL12 (C-X-C Motif Chemokine Ligand 12) and/or CXCR4 (C-X-C motif chemokine receptor 4) levels as markers of TIAR for the early or preliminary stage and/or increased risk of adenomyosis or endometriosis was submitted by Dr. Leyendecker (WO 2019/106034). Here, CXCR4 is linked to adenomyosis.